Marina Nikitović1,2, Dragana Stanić3, Tatjana Pekmezović4,5, Milica Skender Gazibara4,6, Jelena Bokun3,7, Lejla Paripović7, Danica Grujičić4,8, Milan Sarić3, Ivana Mišković3. 1. Faculty of Medicine, University of Belgrade, Dr Subotica 8, 11000, Belgrade, Serbia. marina.nikitovic@ncrc.ac.rs. 2. Institute for Oncology and Radiology of Serbia, Clinic for Radiation Oncology, Pasterova 14, 11000, Belgrade, Serbia. marina.nikitovic@ncrc.ac.rs. 3. Institute for Oncology and Radiology of Serbia, Clinic for Radiation Oncology, Pasterova 14, 11000, Belgrade, Serbia. 4. Faculty of Medicine, University of Belgrade, Dr Subotica 8, 11000, Belgrade, Serbia. 5. Institute of Epidemiology, Faculty of Medicine, University of Belgrade, Visegradska 26, 11000, Belgrade, Serbia. 6. Institute of Pathology, Faculty of Medicine, University of Belgrade, Pasterova 1, 11000, Belgrade, Serbia. 7. Institute for Oncology and Radiology of Serbia, Clinic for Pediatric Oncology, Pasterova 14, 11000, Belgrade, Serbia. 8. Clinic of Neurosurgery, Clinical Center of Serbia, Koste Todorovica 4, 11000, Belgrade, Serbia.
Abstract
PURPOSE: The aim of this study was to evaluate characteristics of childhood glioblastoma multiforme, effectiveness of treatment modalities, and detect factors related to outcome. METHODS: A detailed analysis was performed on a series of 15 patients treated between 2000 and 2013, based on their clinical, radiologic, pathologic, treatment, and follow-up data. RESULTS: Median survival time of children with glioblastoma was 13.5 months. One- and 2-year overall survival probabilities were 66.7 and 20 %, respectively. There were no significant differences in survival based on patients' gender, age, disease presentation with or without epileptic seizures, signs/symptoms of increased intracranial pressure, or tumor location. The presence of neurological deficit initially, as well as prior to radiotherapy, which was quantified by neurologic function score (NFS), had an impact on overall survival. Children with NFS 0 lived longer compared to others (p = 0.001). Survival of children that underwent gross total resection was longer than that of children that underwent subtotal resection (p = 0.030). Mean survival time of children with gross total resection was 73.5 months, compared to 13 months in children with subtotal resection. There was no significant correlation between outcome and type of radiotherapy. In four patients with gigantocellular glioblastoma, we found no evidence of a better prognosis. Two long-term survivors were recorded. Both of them underwent gross total resection and were assigned a NFS 0. CONCLUSIONS: Gross total resection is essential for longer overall survival among pediatric patients with glioblastoma and offers a possibility for long-term survival. Severity of neurologic symptoms quantified by NFS can be considered as a potential predictor of outcome.
PURPOSE: The aim of this study was to evaluate characteristics of childhood glioblastoma multiforme, effectiveness of treatment modalities, and detect factors related to outcome. METHODS: A detailed analysis was performed on a series of 15 patients treated between 2000 and 2013, based on their clinical, radiologic, pathologic, treatment, and follow-up data. RESULTS: Median survival time of children with glioblastoma was 13.5 months. One- and 2-year overall survival probabilities were 66.7 and 20 %, respectively. There were no significant differences in survival based on patients' gender, age, disease presentation with or without epilepticseizures, signs/symptoms of increased intracranial pressure, or tumor location. The presence of neurological deficit initially, as well as prior to radiotherapy, which was quantified by neurologic function score (NFS), had an impact on overall survival. Children with NFS 0 lived longer compared to others (p = 0.001). Survival of children that underwent gross total resection was longer than that of children that underwent subtotal resection (p = 0.030). Mean survival time of children with gross total resection was 73.5 months, compared to 13 months in children with subtotal resection. There was no significant correlation between outcome and type of radiotherapy. In four patients with gigantocellular glioblastoma, we found no evidence of a better prognosis. Two long-term survivors were recorded. Both of them underwent gross total resection and were assigned a NFS 0. CONCLUSIONS: Gross total resection is essential for longer overall survival among pediatric patients with glioblastoma and offers a possibility for long-term survival. Severity of neurologic symptoms quantified by NFS can be considered as a potential predictor of outcome.
Authors: L S Lashford; P Thiesse; A Jouvet; T Jaspan; D Couanet; P D Griffiths; F Doz; J Ironside; K Robson; R Hobson; M Dugan; A D J Pearson; G Vassal; D Frappaz Journal: J Clin Oncol Date: 2002-12-15 Impact factor: 44.544
Authors: Stephanie M Perkins; Joshua B Rubin; Jeffrey R Leonard; Matthew D Smyth; Issam El Naqa; Jeff M Michalski; Joseph R Simpson; David L Limbrick; Tae S Park; David B Mansur Journal: Int J Radiat Oncol Biol Phys Date: 2011-01-08 Impact factor: 7.038
Authors: Federico Sánchez-Herrera; Eduardo Castro-Sierra; Luis Felipe Gordillo-Domínguez; Miguel Angel Vaca-Ruiz; Blanca Santana-Montero; Mario Perezpeña-Diazconti; Vicente González-Carranza; Samuel Torres-García; Fernando Chico-Ponce de León Journal: Childs Nerv Syst Date: 2009-01-16 Impact factor: 1.475
Authors: Michael Karremann; Sandra Butenhoff; Ulrike Rausche; Torsten Pietsch; Johannes E A Wolff; Christof M Kramm Journal: Neuro Oncol Date: 2008-12-02 Impact factor: 12.300
Authors: Dominik Sturm; Sebastian Bender; David T W Jones; Peter Lichter; Jacques Grill; Oren Becher; Cynthia Hawkins; Jacek Majewski; Chris Jones; Joseph F Costello; Antonio Iavarone; Kenneth Aldape; Cameron W Brennan; Nada Jabado; Stefan M Pfister Journal: Nat Rev Cancer Date: 2014-02 Impact factor: 60.716
Authors: Alok Mohan Uppar; Harsha Sugur; A R Prabhuraj; M Bhaskara Rao; B Indira Devi; S Sampath; A Arivazhagan; Vani Santosh Journal: Childs Nerv Syst Date: 2019-05-31 Impact factor: 1.475
Authors: Rosy Njonkou; Christopher M Jackson; Graeme F Woodworth; David S Hersh Journal: Cancer Immunol Immunother Date: 2022-01-12 Impact factor: 6.630
Authors: Joshua D Bernstock; Zachary Wright; Asim K Bag; Florian Gessler; George Yancey Gillespie; James M Markert; Gregory K Friedman; James M Johnston Journal: World Neurosurg Date: 2018-11-24 Impact factor: 2.104
Authors: Abdulrahman Al Shudifat; Hala Al Suqi; Kutada Soub; Leen Al Nemrawi; Moa'tasem Abu Jaber; Mohammad Al Barbarawi; Nour Shewaikani; Yazan El Adwan; Assem Al Refaei Journal: Risk Manag Healthc Policy Date: 2021-09-27
Authors: Rami Hatoum; Jia-Shu Chen; Pascal Lavergne; Nathan A Shlobin; Andrew Wang; Lior M Elkaim; Philippe Dodin; Charles P Couturier; George M Ibrahim; Aria Fallah; Dominic Venne; Sebastien Perreault; Anthony C Wang; Nada Jabado; Roy W R Dudley; Alexander G Weil Journal: JAMA Netw Open Date: 2022-08-01
Authors: Dragana Stanić; Danica Grujičić; Tatjana Pekmezović; Jelena Bokun; Marija Popović-Vuković; Dragana Janić; Lejla Paripović; Vesna Ilić; Marija Pudrlja Slović; Rosanda Ilić; Savo Raičević; Milan Sarić; Ivana Mišković; Borko Nidžović; Marina Nikitović Journal: PLoS One Date: 2021-10-26 Impact factor: 3.240